ArticleMedicine2025
Identification of a disulfidptosis-correlated ferroptosis prognostic model in breast cancer.
Article in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Targeting the urgent need for diagnostic biomarkers in breast cancer, the most common female malignancy, this study evaluates the diagnostic and prognostic potential of disulfidptosis-related ferroptosis genes (DRFGs), leveraging the emerging roles of disulfidptosis and ferroptosis in cancer biology. Ferroptosis- and disulfidptosis-related genes of patients with breast cancer were collected from The Cancer Genome Atlas database, then 154 identified prognosis-associated DRFGs were analyzed using Pearson correlation analysis, and developed a DRFG-associated risk model containing 19 DRFGs by applying the least absolute shrinkage and selection operator Cox regression analysis. We then assessed the prognostic performance of the risk model between the high- and low-risk groups. The risk scores and clinical variables were combined to construct a nomogram. Bioinformatics analyses including functional enrichment analysis and protein-protein interaction networks were conducted. Besides, we examined the biological functions, immune checkpoints, and drug sensitivity of the model. Finally, ANO6 overexpression effects on breast cancer cell invasion and metastasis were examined via wound healing and Transwell assays. The high-risk group showed poorer overall survival (OS) rates (P <.001) and lower receiver operating characteristic curve area under receiver operating characteristic values compared to the low-risk group. The results of univariate and multivariate Cox regression analyses confirmed that the established nomogram model served as an independent prognostic indicator. Functional enrichment analysis revealed the involvement of DRFGs in biological processes and signaling pathways beyond disulfidptosis and ferroptosis. The level of expressions of immune checkpoints for TDO2 and PVR were increased in the high-risk group. Drug sensitivity analysis showed that high-risk patients benefited more from AKT.inhibitor.VIII. Moreover, anoctamin 6 overexpression inhibited breast cancer cell invasion and metastasis. This study successfully established a DRFG-related prognostic model for patients with breast cancer, and anoctamin 6 has emerged as a promising therapeutic target for breast cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.